scispace - formally typeset
R

Robert L. Keith

Researcher at Veterans Health Administration

Publications -  100
Citations -  3492

Robert L. Keith is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 30, co-authored 88 publications receiving 3047 citations. Previous affiliations of Robert L. Keith include East Tennessee State University & University of Colorado Hospital.

Papers
More filters
Journal ArticleDOI

The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution

Orit Rozenblatt-Rosen, +373 more
- 16 Apr 2020 - 
TL;DR: The Human Tumor Atlas Network (HTAN), part of the NCI Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types.
Journal Article

Angiogenic Squamous Dysplasia in Bronchi of Individuals at High Risk for Lung Cancer

TL;DR: Fluorescence bronchoscopy in smokers at high risk for lung cancer observed a unique lesion consisting of capillary blood vessels closely juxtaposed to and projecting into metaplastic or dysplastic squamous bronchial epithelium, angiogenic squamous dysplasia (ASD), a qualitatively distinct form of angiogenesis in which there is architectural rearrangement of the capillary microvasculature.
Journal ArticleDOI

Hypoxia induces different genes in the lungs of rats compared with mice

TL;DR: It is proposed that a balance between over- and under-expression of a selective group of genes may be responsible for lung vascular remodeling and vascular tone control.
Journal ArticleDOI

Treatment of Non-small Cell Lung Cancer, Stage IIIB: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)

TL;DR: Prospective trials are needed to answer important questions, such as the role of induction therapy in patients with potentially resectable stage IIIB disease, and the questions of optimal chemotherapy agents and radiation fractionation schedule.